The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis
2011
The Role of IL-6 in Systemic Sclerosis
publication
Evidence: moderate
Author Information
Author(s): Theresa C. Barnes, Marina E. Anderson, Robert J. Moots
Primary Institution: University of Liverpool
Hypothesis
Is interleukin-6 a potential therapeutic target in systemic sclerosis?
Conclusion
Blocking IL-6 signaling may improve treatment options for systemic sclerosis.
Supporting Evidence
- IL-6 is elevated in the serum of patients with systemic sclerosis, especially in early disease.
- B-cell depletion using rituximab resulted in a decrease in serum IL-6 concentration.
- Blocking IL-6 trans-signaling with Tocilizumab improved skin score in patients with diffuse disease.
- Fibroblasts from SSc patients produce higher levels of IL-6 than healthy controls.
- IL-6 may play a role in endothelial cell dysfunction and fibrogenesis in systemic sclerosis.
Takeaway
Interleukin-6 is a protein that can cause problems in a disease called systemic sclerosis, and stopping it might help people feel better.
Methodology
The paper reviews existing evidence and discusses the role of IL-6 in systemic sclerosis.
Limitations
The study is based on existing literature and may not include new experimental data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website